Welcome to our dedicated page for Sotera Health Co news (Ticker: SHC), a resource for investors and traders seeking the latest updates and insights on Sotera Health Co stock.
Sotera Health Company (NASDAQ: SHC) is described as a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. Through its Sterigenics, Nordion and Nelson Labs businesses, the company focuses on sterilization, analytical testing and related services that support the safety of medical, pharmaceutical and food products.
The SHC news feed on Stock Titan highlights company announcements that matter to investors and observers of the healthcare services and testing laboratories space. These include quarterly and year-to-date financial results, updates on revenue trends and segment performance for Sterigenics, Nordion and Nelson Labs, as well as information on leverage, credit facilities and other balance sheet items described in press releases and Form 8-K filings.
Users can also follow news about secondary offerings of common stock by selling stockholders, as disclosed in company press releases and related 8-K filings. These items explain when affiliates of investment firms have sold blocks of SHC shares and clarify that Sotera Health did not receive proceeds from those transactions.
Regulatory and legal developments are another important category of news for Sotera Health. Public disclosures describe litigation and settlements related to ethylene oxide emissions at certain Sterigenics facilities, along with broader risk discussions around EO, Co-60 supply, regulatory changes and international operations. Conference participation, earnings release dates and management presentations at healthcare investor events are also covered in the company’s news flow.
By reviewing this news stream, readers can see how Sotera Health communicates its financial performance, capital markets activity, legal developments and strategic positioning in sterilization and lab testing services over time.
Sotera Health (Nasdaq: SHC) has announced a secondary offering of 20 million shares of its common stock. The offering is being conducted by selling stockholders affiliated with Warburg Pincus and GTCR, with Goldman Sachs & Co. LLC serving as the underwriter.
The company itself is not selling any shares and will not receive any proceeds from the offering, although it will cover the offering expenses per its Amended and Restated Registration Rights Agreement. The offering will be made through a prospectus, with a registration statement already filed and effective with the SEC.
Sotera Health (NASDAQ:SHC) reported strong Q2 2025 results with net revenues increasing 6.4% to $294 million. The company posted net income of $8 million ($0.03 per diluted share) and Adjusted EBITDA grew 9.8% to $151 million.
Key segment performance includes Sterigenics' revenue growth of 10.5% to $195 million, Nordion's increase of 2.9% to $42 million, while Nelson Labs saw a decline of 3.3% to $57 million. The company raised its full-year 2025 outlook, now expecting net revenue growth of 4.5% - 6.0% and Adjusted EBITDA growth of 6.0% - 7.5% on a constant currency basis.
The company maintains a strong balance sheet with $2.3 billion in total debt and $332 million in unrestricted cash, with an improved Net Leverage Ratio of 3.5x.
[ "Q2 net revenues increased 6.4% to $294 million", "Adjusted EBITDA grew 9.8% to $151 million with 160 basis points margin expansion", "Sterigenics segment showed strong 10.5% revenue growth to $195 million", "Company raised full-year 2025 outlook for revenue and Adjusted EBITDA", "Net Leverage Ratio improved to 3.5x from 3.7x", "No balance outstanding on $600 million revolving credit facility" ]Sotera Health (Nasdaq: SHC), a leading provider of sterilization solutions and lab testing services for the healthcare industry, has scheduled its second-quarter 2025 financial results release for August 8, 2025, before market open.
The company will host a conference call at 9:00 a.m. EDT to discuss results and operating highlights. Investors can participate via phone (US toll-free: 1-844-481-2916; International: 1-412-317-0709) or access the live webcast through the company's Investor Relations website. Conference materials will be available, and a webcast replay will be posted later that day.
[]Sotera Health (Nasdaq: SHC), a leading global provider of sterilization solutions and lab testing services for the healthcare industry, has scheduled its first-quarter 2025 financial results release for Thursday, May 1, 2025, before market opening.
The company will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss Q1 2025 results and operating highlights. Participants can join via phone (1-844-481-2916 US toll-free; 1-412-317-0709 international) or access the live webcast through the Investor Relations section of Sotera Health's website. Conference materials will be available, and a webcast replay will be accessible later that day.
Nelson Labs, a Sotera Health company, has launched Rapid Sterility Testing services at three laboratory sites across the United States and Europe. This innovative testing method reduces product sterility test results time from the traditional 14-day period to as little as 6 days, while maintaining compliance with USP <71> and <1223> standards.
The new testing solution uniquely supports both medical device and pharmaceutical products, expanding beyond the typical focus on biological components or short shelf-life products. The method employs quantitative data instrumentation to automate test results, reducing human error potential. This advancement enables faster product release while maintaining quality and safety standards.
Sotera Health (Nasdaq: SHC) reported its Q4 and full-year 2024 results, showing mixed performance. Full-year 2024 highlights include:
- Net revenues increased 4.9% to $1.10 billion
- Net income of $44 million ($0.16 per diluted share)
- Adjusted EBITDA grew 3.9% to $549 million
However, Q4 2024 showed some weakness:
- Net revenues decreased 6.5% to $290 million
- Net income dropped to $12 million ($0.04 per diluted share)
- Adjusted EBITDA declined 8.3% to $153 million
For 2025 outlook, the company projects:
- Net revenues growth of 4.0% - 6.0%
- Adjusted EBITDA growth of 4.5% - 6.5%
- Adjusted EPS range of $0.70 to $0.76
Sotera Health Company (Nasdaq: SHC), a leading global provider of sterilization solutions and lab testing services for the healthcare industry, has scheduled its fourth-quarter and full-year 2024 financial results release for Thursday, February 27, 2025, before market opening.
The company will host a conference call at 9:00 a.m. Eastern Time to discuss operating highlights and financial results. Participants can join by dialing 1-844-481-2916 (US) or 1-412-317-0709 (international locations). A live webcast and accompanying materials will be accessible through the company's Investor Relations website, with a replay available later that day.
Sotera Health (Nasdaq: SHC) presented at the 43rd Annual J.P. Morgan Healthcare Conference, where Chairman and CEO Michael B. Petras, Jr. provided a business update. The company, a leading provider of sterilization solutions and lab testing services for the healthcare industry, expects to report full-year revenues of approximately $1.1 billion for 2024, representing nearly 5% growth compared to 2023 and over 5% growth on a constant currency basis.
The company's management team, including CFO Jon Lyons and VP of Investor Relations Jason Peterson, are participating in investor meetings during the conference. A live webcast of the presentation is available on the company's website, with a replay to be archived. Full 2024 financial results and 2025 outlook will be reported on February 27, 2025.
Sotera Health Company (NASDAQ: SHC), a leading global provider of sterilization solutions, lab testing, and healthcare advisory services, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Chairman and CEO Michael B. Petras, Jr. will deliver a presentation on Tuesday, January 14, 2025, at 11:15 a.m. Eastern Time.
The company's senior leadership team, including CFO Jon Lyons and VP of Investor Relations Jason Peterson, will engage in investor meetings throughout the conference. Investors and interested parties can access a live webcast of the presentation through Sotera Health's Investor Relations website section under Presentations & Events. The presentation materials will be available for viewing, and a replay will be accessible within 48 hours after the conference concludes.